← Back to Clinical Trials
RecruitingNCT04961580

PK/PD of Ceftazidime Avitbatan Sodium in Children With Severe Infection

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionSepsis
SponsorChildren's Hospital of Fudan University
Study TypeOBSERVATIONAL
PhaseN/A
Enrollment30
SexALL
Min Age3 Months
Max Age18 Years
Start Date2022-10-01
Completion2026-12-31
Interventions
Ceftazidime Avitbatan Sodium

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Ceftazidime avitbatan sodium is a broad-spectrum antibiotic with an antimicrobial spectrum covering resistant gram-negative bacteria. Its use in pediatric intensive care for severe infections is not unusual. Pathophysiological changes in severe sepsis can lead to significant changes in pharmacokinetics and pharmacodynamics during continuous renal replacement therapy.This research aims to study change of pharmacokinetic and pharmacodynamic in severe infection children with extracorporeal life support, thus improve the treatment of severe sepsis and sepsis shock.

Eligibility Criteria

Inclusion Criteria: * Children who are admitted in the pediatric intensive care unit receiving ceftazidime avitbatan sodium Exclusion Criteria: * No Informed Consent signed * Participate in other clinical trials

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology